

Bartolome R Celli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5873063/publications.pdf>

Version: 2024-02-01

323
papers

40,949
citations

4136

87
h-index

2567

195
g-index

398
all docs

398
docs citations

398
times ranked

22176
citing authors

#	ARTICLE	IF	CITATIONS
1	The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2004, 350, 1005-1012.	13.9	3,409
2	Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2007, 356, 775-789.	13.9	2,963
3	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 557-582.	2.5	2,393
4	A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2008, 359, 1543-1554.	13.9	1,969
5	American Thoracic Society/European Respiratory Society Statement on Pulmonary Rehabilitation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 1390-1413.	2.5	1,644
6	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. <i>European Respiratory Journal</i> , 2019, 53, 1900164.	3.1	1,223
7	Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2015, 373, 111-122.	13.9	974
8	Characterisation of COPD heterogeneity in the ECLIPSE cohort. <i>Respiratory Research</i> , 2010, 11, 122.	1.4	952
9	Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 155-161.	2.5	946
10	Chronic Obstructive Pulmonary Disease Phenotypes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 598-604.	2.5	898
11	Changes in Forced Expiratory Volume in 1 Second over Time in COPD. <i>New England Journal of Medicine</i> , 2011, 365, 1184-1192.	13.9	811
12	Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 332-338.	2.5	692
13	Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype. <i>PLoS ONE</i> , 2012, 7, e37483.	1.1	633
14	Outcomes in Patients with Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 325-331.	2.5	589
15	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>European Respiratory Journal</i> , 2017, 49, 1700214.	3.1	536
16	Inspiratory-to-Total Lung Capacity Ratio Predicts Mortality in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 171, 591-597.	2.5	514
17	Chronic obstructive pulmonary disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15076.	18.1	444
18	Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. <i>Lancet</i> , The, 2009, 374, 1171-1178.	6.3	430

#	ARTICLE	IF	CITATIONS
19	Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. <i>Lancet</i> , The, 2016, 387, 1817-1826.	6.3	378
20	Inflammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 1065-1072.	2.5	353
21	Association Between Interstitial Lung Abnormalities and All-Cause Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 672.	3.8	333
22	Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. <i>Respiratory Medicine</i> , 2013, 107, 1376-1384.	1.3	328
23	Long-term Controlled Trial of Nocturnal Nasal Positive Pressure Ventilation in Patients With Severe COPD. <i>Chest</i> , 2000, 118, 1582-1590.	0.4	312
24	Informe 2017 de la Iniciativa Global para el Diagnóstico, Tratamiento y Prevención de la Enfermedad Pulmonar Obstructiva Crónica: Resumen Ejecutivo de GOLD. <i>Archivos De Bronconeumologia</i> , 2017, 53, 128-149.	0.4	312
25	Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report. <i>Respirology</i> , 2017, 22, 575-601.	1.3	299
26	Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. <i>Respiratory Research</i> , 2009, 10, 59.	1.4	287
27	What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. <i>European Respiratory Journal</i> , 2016, 48, 664-673.	3.1	287
28	Improvement in Resting Inspiratory Capacity and Hyperinflation With Tiotropium in COPD Patients With Increased Static Lung Volumes *. <i>Chest</i> , 2003, 124, 1743-1748.	0.4	278
29	Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 913-919.	2.5	266
30	Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2019, 381, 1257-1266.	13.9	264
31	Six-Minute-Walk Test in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 382-386.	2.5	257
32	Distance and Oxygen Desaturation During the 6-min Walk Test as Predictors of Long-term Mortality in Patients With COPD. <i>Chest</i> , 2008, 134, 746-752.	0.4	254
33	Mortality in the 4-Year Trial of Tiotropium (UPLIFT) in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 948-955.	2.5	252
34	Prevalence and Progression of Osteoporosis in Patients With COPD. <i>Chest</i> , 2009, 136, 1456-1465.	0.4	240
35	Prevention of Acute Exacerbations of COPD. <i>Chest</i> , 2015, 147, 894-942.	0.4	230
36	The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. <i>Lancet Respiratory Medicine</i> , the, 2013, 1, 129-136.	5.2	224

#	ARTICLE	IF	CITATIONS
37	Impact of COPD Exacerbations on Patient-Centered Outcomes. Chest, 2007, 131, 696-704.	0.4	219
38	Power of Outcome Measurements to Detect Clinically Significant Changes in Pulmonary Rehabilitation of Patients With COPD. Chest, 2002, 121, 1092-1098.	0.4	214
39	Gender and COPD in Patients Attending a Pulmonary Clinic. Chest, 2005, 128, 2012-2016.	0.4	214
40	Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD. Chest, 2006, 130, 647-656.	0.4	205
41	The 6-Min Walk Distance, Peak Oxygen Uptake, and Mortality in COPD. Chest, 2007, 132, 1778-1785.	0.4	205
42	The Progression of Chronic Obstructive Pulmonary Disease Is Heterogeneous. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1015-1021.	2.5	197
43	Predicting Outcomes from 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease. Journal of the American Medical Directors Association, 2012, 13, 291-297.	1.2	193
44	Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A <i>Post Hoc</i> Cohort Analysis from the SUMMIT Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 51-57.	2.5	192
45	At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1540-1551.	2.5	185
46	Benralizumab for the Prevention of COPD Exacerbations. New England Journal of Medicine, 2019, 381, 1023-1034.	13.9	180
47	Cardiovascular events in patients with COPD: TORCH Study results. Thorax, 2010, 65, 719-725.	2.7	177
48	Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet, The, 2021, 397, 928-940.	6.3	176
49	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Archivos De Bronconeumologia, 2017, 53, 128-149.	0.4	173
50	Determinants of poor 6-min walking distance in patients with COPD: The ECLIPSE cohort. Respiratory Medicine, 2010, 104, 849-857.	1.3	171
51	Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax, 2007, 62, 595-601.	2.7	170
52	Addressing the Complexity of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1129-1137.	2.5	166
53	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, e4-e27.	2.5	166
54	Inhaled corticosteroids in COPD: friend or foe?. European Respiratory Journal, 2018, 52, 1801219.	3.1	166

#	ARTICLE	IF	CITATIONS
55	Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. <i>European Respiratory Journal</i> , 2013, 42, 636-646.	3.1	164
56	Impact and prevention of severe exacerbations of COPD: a review of the evidence. <i>International Journal of COPD</i> , 2017, Volume 12, 2891-2908.	0.9	162
57	Gene Expression Profiling of Human Lung Tissue from Smokers with Severe Emphysema. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2004, 31, 601-610.	1.4	159
58	Sex Differences in Mortality and Clinical Expressions of Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 317-322.	2.5	157
59	Airway obstruction in never smokers: Results from the Third National Health and Nutrition Examination Survey. <i>American Journal of Medicine</i> , 2005, 118, 1364-1372.	0.6	156
60	Clinical Trial Design Considerations in Assessing Long-Term Functional Impacts of Tiotropium in COPD: The Uplift Trial. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2004, 1, 303-312.	0.7	152
61	Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. <i>Thorax</i> , 2014, 69, 718-723.	2.7	151
62	Predictors of mortality in COPD. <i>Respiratory Medicine</i> , 2010, 104, 773-779.	1.3	145
63	COPD comorbidities network. <i>European Respiratory Journal</i> , 2015, 46, 640-650.	3.1	145
64	Once-Daily Umeclidinium/Vilanterol 125/25 $\hat{1}$ / $\hat{4}$ g Therapy in COPD. <i>Chest</i> , 2014, 145, 981-991.	0.4	142
65	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Journal</i> , 2015, 45, 879-905.	3.1	138
66	Should We View Chronic Obstructive Pulmonary Disease Differently after ECLIPSE?. A Clinical Perspective from the Study Team. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 1022-1030.	2.5	130
67	Markers of disease severity in chronic obstructive pulmonary disease. <i>Pulmonary Pharmacology and Therapeutics</i> , 2006, 19, 189-199.	1.1	127
68	C-Reactive Protein Levels and Survival in Patients With Moderate to Very Severe COPD. <i>Chest</i> , 2008, 133, 1336-1343.	0.4	127
69	Identification of Five Chronic Obstructive Pulmonary Disease Subgroups with Different Prognoses in the ECLIPSE Cohort Using Cluster Analysis. <i>Annals of the American Thoracic Society</i> , 2015, 12, 303-312.	1.5	126
70	Biological Lung Volume Reduction. <i>Chest</i> , 2007, 131, 1108-1113.	0.4	125
71	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. <i>Lancet Respiratory Medicine</i> , 2015, 3, 443-450.	5.2	125
72	Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. <i>European Respiratory Journal</i> , 2017, 50, 1701162.	3.1	122

#	ARTICLE	IF	CITATIONS
73	An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1251-1258.	2.5	121
74	Distribution and Prognostic Validity of the New Global Initiative for Chronic Obstructive Lung Disease Grading Classification. <i>Chest</i> , 2013, 143, 694-702.	0.4	120
75	From GOLD 0 to Pre-COPD. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 414-423.	2.5	119
76	Systemic Cytokines, Clinical and Physiological Changes in Patients Hospitalized for Exacerbation of COPD. <i>Chest</i> , 2007, 131, 37-43.	0.4	117
77	Predictors of Survival in COPD: More than Just the FEV1. <i>Respiratory Medicine</i> , 2008, 102, S27-S35.	1.3	117
78	Genome-Wide Association Analysis of Blood Biomarkers in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 1238-1247.	2.5	117
79	Prediction of risk of COPD exacerbations by the BODE index. <i>Respiratory Medicine</i> , 2009, 103, 373-378.	1.3	116
80	Protective role for club cell secretory protein-16 (CC16) in the development of COPD. <i>European Respiratory Journal</i> , 2015, 45, 1544-1556.	3.1	115
81	Longitudinal Change in the BODE Index Predicts Mortality in Severe Emphysema. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 491-499.	2.5	114
82	Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1000-1011.	2.5	111
83	Update on the Management of COPD. <i>Chest</i> , 2008, 133, 1451-1462.	0.4	103
84	Gender associated differences in determinants of quality of life in patients with COPD: a case series study. <i>Health and Quality of Life Outcomes</i> , 2006, 4, 72.	1.0	98
85	Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. <i>Respiratory Medicine</i> , 2011, 105, 580-587.	1.3	96
86	Benefits of Long-Term Pulmonary Rehabilitation Maintenance Program in Patients with Severe Chronic Obstructive Pulmonary Disease. Three-Year Follow-up. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 622-629.	2.5	94
87	Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1195-1204.	2.5	94
88	Multicomponent indices to predict survival in COPD: the COCOMICS study. <i>European Respiratory Journal</i> , 2013, 42, 323-332.	3.1	93
89	COPD as an endothelial disorder: endothelial injury linking lesions in the lungs and other organs? (2017 Grover Conference Series). <i>Pulmonary Circulation</i> , 2018, 8, 1-18.	0.8	90
90	B Cell-Activating Factor. An Orchestrator of Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 695-705.	2.5	89

#	ARTICLE	IF	CITATIONS
91	Long-Term Noninvasive Ventilation in Chronic Stable Hypercapnic Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e74-e87.	2.5	87
92	COPD: time to improve its taxonomy?. ERJ Open Research, 2018, 4, 00132-2017.	1.1	84
93	The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1483-1493.	2.5	83
94	Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE. Thorax, 2014, 69, 799-804.	2.7	82
95	The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. European Respiratory Journal, 2013, 41, 1017-1022.	3.1	81
96	Bronchodilator Reversibility in COPD. Chest, 2011, 140, 1055-1063.	0.4	80
97	Bias due to withdrawal in long-term randomised trials in COPD: Evidence from the TORCH study. Clinical Respiratory Journal, 2011, 5, 44-49.	0.6	78
98	What does endotyping mean for treatment in chronic obstructive pulmonary disease?. Lancet, The, 2017, 390, 980-987.	6.3	78
99	Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study. Respiratory Medicine, 2015, 109, 1138-1146.	1.3	77
100	Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respiratory Medicine, the, 2021, 9, 1288-1298.	5.2	75
101	DNA methylation profiling in human lung tissue identifies genes associated with COPD. Epigenetics, 2016, 11, 730-739.	1.3	73
102	Microalbuminuria and Hypoxemia in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1004-1010.	2.5	72
103	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Review, 2015, 24, 159-172.	3.0	72
104	Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-“Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 275-287.	2.5	72
105	Chronic Obstructive Pulmonary Disease (COPD) as a disease of early aging: Evidence from the EpiChron Cohort. PLoS ONE, 2018, 13, e0193143.	1.1	70
106	Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Lancet Respiratory Medicine, the, 2020, 8, 158-170.	5.2	69
107	Effect of tiotropium in men and women with COPD: Results of the 4-year UPLIFT® trial. Respiratory Medicine, 2010, 104, 1495-1504.	1.3	68
108	The COPD Biomarker Qualification Consortium (CBQC). COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 367-377.	0.7	67

#	ARTICLE	IF	CITATIONS
109	Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. <i>Respirology</i> , 2021, 26, 532-551.	1.3	67
110	Itâ€™s more than low BMI: prevalence of cachexia and associated mortality in COPD. <i>Respiratory Research</i> , 2019, 20, 100.	1.4	66
111	Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. <i>Respiratory Care</i> , 2006, 51, 1120-4.	0.8	66
112	Deterioration of Limb Muscle Function during Acute Exacerbation of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 433-449.	2.5	64
113	Comparison of the 2017 and 2015 Global Initiative for Chronic Obstructive Lung Disease Reports. Impact on Grouping and Outcomes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 463-469.	2.5	63
114	Machine Learning and Prediction of All-Cause Mortality in COPD. <i>Chest</i> , 2020, 158, 952-964.	0.4	62
115	Gender and respiratory factors associated with dyspnea in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2007, 8, 18.	1.4	61
116	Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. <i>Respiratory Research</i> , 2011, 12, 71.	1.4	60
117	Rapid Lung Function Decline in Smokers Is a Risk Factor for COPD and Is Attenuated by Angiotensin-Converting Enzyme Inhibitor Use. <i>Chest</i> , 2014, 145, 695-703.	0.4	60
118	Club Cell Protein 16 (CC16) Augmentation: A Potential Disease-modifying Approach for Chronic Obstructive Pulmonary Disease (COPD). <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 869-883.	1.5	60
119	Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype. <i>European Respiratory Journal</i> , 2018, 51, 1702146.	3.1	60
120	Ventilatory Drive at Rest and Perception of Exertional Dyspnea in Severe COPD. <i>Chest</i> , 1999, 115, 1293-1300.	0.4	59
121	Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2005, 99, 1546-1554.	1.3	59
122	Disease progression in young patients with COPD: rethinking the Fletcher and Peto model. <i>European Respiratory Journal</i> , 2014, 44, 324-331.	3.1	57
123	Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. <i>International Journal of COPD</i> , 2018, Volume 13, 3971-3981.	0.9	56
124	Identification of COPD Patients at High Risk for Lung Cancer Mortality Using the COPD-LUCSS-DLCO. <i>Chest</i> , 2016, 149, 936-942.	0.4	55
125	Roger S. Mitchell Lecture. Chronic Obstructive Pulmonary Disease Phenotypes and Their Clinical Relevance. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 461-465.	3.5	54
126	Lung Volume Reduction Therapies for Advanced Emphysema. <i>Chest</i> , 2010, 138, 407-417.	0.4	53

#	ARTICLE	IF	CITATIONS
127	Prognostic assessment in COPD: Health related quality of life and the BODE index. <i>Respiratory Medicine</i> , 2011, 105, 916-921.	1.3	53
128	Handgrip weakness and mortality risk in COPD: a multicentre analysis. <i>Thorax</i> , 2016, 71, 86-87.	2.7	53
129	Different dyspnoea perception in COPD patients with frequent and infrequent exacerbations. <i>Thorax</i> , 2017, 72, 117-121.	2.7	53
130	Effect of a single exacerbation on decline in lung function in COPD. <i>Respiratory Medicine</i> , 2017, 128, 85-91.	1.3	53
131	A simple algorithm for the identification of clinical COPD phenotypes. <i>European Respiratory Journal</i> , 2017, 50, 1701034.	3.1	53
132	Executive Summary. <i>Chest</i> , 2015, 147, 883-893.	0.4	51
133	Differences in Cardiopulmonary Exercise Test Results by American Thoracic Society/European Respiratory Society-Global Initiative for Chronic Obstructive Lung Disease Stage Categories and Gender. <i>Chest</i> , 2007, 132, 1204-1211.	0.4	50
134	Genome-Wide Association Analysis of Body Mass in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 45, 304-310.	1.4	50
135	Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: A pilot study. <i>Respiratory Medicine</i> , 2013, 107, 702-707.	1.3	50
136	Sex differences between women and men with COPD: A new analysis of the 3CIA study. <i>Respiratory Medicine</i> , 2020, 171, 106105.	1.3	50
137	Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 881-888.	2.5	49
138	Metformin: Experimental and Clinical Evidence for a Potential Role in Emphysema Treatment. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 651-666.	2.5	49
139	Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1126-1137.	1.2	48
140	Chronic Obstructive Pulmonary Disease: From Unjustified Nihilism to Evidence-based Optimism. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 58-65.	3.5	47
141	Sexually-dimorphic targeting of functionally-related genes in COPD. <i>BMC Systems Biology</i> , 2014, 8, 118.	3.0	47
142	Point: Should We Abandon FEV ₁ /FVC <0.70 To Detect Airway Obstruction? No. <i>Chest</i> , 2010, 138, 1037-1040.	0.4	46
143	Changes in Body Composition in Patients with Chronic Obstructive Pulmonary Disease: Do They Influence Patient-Related Outcomes?. <i>Annals of Nutrition and Metabolism</i> , 2013, 63, 239-247.	1.0	46
144	Telomere shortening and accelerated aging in COPD: findings from the BODE cohort. <i>Respiratory Research</i> , 2017, 18, 59.	1.4	46

#	ARTICLE	IF	CITATIONS
145	Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 47-55.	2.5	46
146	Gender Differences in Plasma Biomarker Levels in a Cohort of COPD Patients: A Pilot Study. <i>PLoS ONE</i> , 2011, 6, e16021.	1.1	44
147	Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. <i>Respirology</i> , 2011, 16, 825-835.	1.3	43
148	Opportunities and Challenges in the Genetics of COPD 2010: An International COPD Genetics Conference Report. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2011, 8, 121-135.	0.7	43
149	Perception of symptoms and quality of life – comparison of patients’ and physicians’ views in the COPD MIRROR study. <i>International Journal of COPD</i> , 2017, Volume 12, 2189-2196.	0.9	43
150	It is time for the world to take COPD seriously: a statement from the GOLD board of directors. <i>European Respiratory Journal</i> , 2019, 54, 1900914.	3.1	43
151	Finding the Best Thresholds of FEV1 and Dyspnea to Predict 5-Year Survival in COPD Patients: The COCOMICS Study. <i>PLoS ONE</i> , 2014, 9, e89866.	1.1	43
152	Treadmill Endurance During 2-Year Treatment With Tiotropium in Patients With COPD. <i>Chest</i> , 2013, 144, 490-497.	0.4	42
153	Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 689-698.	2.5	42
154	Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. <i>Heart</i> , 2017, 103, 1536-1542.	1.2	41
155	Natural history of COPD: gaps and opportunities. <i>ERJ Open Research</i> , 2017, 3, 00117-2017.	1.1	40
156	Multimorbidity in Patients with Chronic Obstructive Pulmonary Disease. <i>Clinics in Chest Medicine</i> , 2020, 41, 405-419.	0.8	38
157	Comorbidity Distribution, Clinical Expression and Survival in COPD Patients with Different Body Mass Index. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2014, 1, 229-238.	0.5	38
158	Time to desaturation in the 6-min walking distance test predicts 24-hour oximetry in COPD patients with a PO2 between 60 and 70mmHg. <i>Respiratory Medicine</i> , 2008, 102, 1026-1032.	1.3	37
159	Longitudinal assessment in COPD patients: multidimensional variability and outcomes. <i>European Respiratory Journal</i> , 2014, 43, 745-753.	3.1	37
160	Prognostic assessment in COPD without lung function: the B-AE-D indices. <i>European Respiratory Journal</i> , 2016, 47, 1635-1644.	3.1	37
161	Spirometric variability in smokers: transitions in COPD diagnosis in a five-year longitudinal study. <i>Respiratory Research</i> , 2016, 17, 147.	1.4	36
162	The Expanding Role of Biomarkers in the Assessment of Smoking-Related Parenchymal Lung Diseases. <i>Chest</i> , 2012, 142, 1027-1034.	0.4	35

#	ARTICLE	IF	CITATIONS
163	<p>₁ is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease</p>. International Journal of COPD, 2020, Volume 15, 1135-1142.	0.9	35
164	The Challenge of Controlling the COPD Epidemic: Unmet Needs. American Journal of Medicine, 2018, 131, 1-6.	0.6	33
165	Time for a change: anticipating the diagnosis and treatment of COPD. European Respiratory Journal, 2020, 56, 2002104.	3.1	33
166	Chronic Obstructive Pulmonary Disease and Lung Cancer. Proceedings of the American Thoracic Society, 2012, 9, 74-79.	3.5	32
167	A comparison of 5-day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clinical Therapeutics, 2003, 25, 542-557.	1.1	31
168	Predictors of Mortality in Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine, 2007, 28, 515-524.	0.8	31
169	A Novel Nonhuman Primate Model of Cigarette Smoke-Induced Airway Disease. American Journal of Pathology, 2015, 185, 741-755.	1.9	31
170	Inhalation Technique Errors with Metered-Dose Inhalers Among Patients with Obstructive Lung Diseases: A Systematic Review and Meta-Analysis of U.S. Studies. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2019, 6, 267-280.	0.5	31
171	Cough and Phlegm Are Important Predictors of Health Status in Smokers Without COPD. Chest, 2002, 121, 1427-1433.	0.4	30
172	Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial. European Heart Journal, 2018, 39, 3128-3134.	1.0	30
173	Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study. Respiratory Medicine, 2016, 119, 87-95.	1.3	29
174	Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. Respiratory Medicine, 2017, 131, 27-34.	1.3	29
175	Clinical Features of Smokers With Radiological Emphysema But Without Airway Limitation. Chest, 2017, 151, 358-365.	0.4	29
176	Use of Proteomic Patterns of Serum Biomarkers in Patients with Chronic Obstructive Pulmonary Disease: Correlation with Clinical Parameters. Proceedings of the American Thoracic Society, 2006, 3, 465-466.	3.5	28
177	Supplementation with Qter® and Creatine improves functional performance in COPD patients on long term oxygen therapy. Respiratory Medicine, 2018, 142, 86-93.	1.3	28
178	Change in the BODE Index Reflects Disease Modification in COPD. Chest, 2006, 129, 835-836.	0.4	27
179	Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine, 2011, 105, 1176-1188.	1.3	27
180	Cigarette smoking and response to inhaled corticosteroids in COPD. European Respiratory Journal, 2018, 51, 1701393.	3.1	27

#	ARTICLE	IF	CITATIONS
181	The role of systemic inflammatory biomarkers to predict mortality in chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2013, 7, 57-64.	1.0	26
182	Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease. International Journal of COPD, 2015, 10, 549.	0.9	26
183	Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial. BMJ Open Respiratory Research, 2019, 6, e000431.	1.2	26
184	Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. European Respiratory Journal, 2021, 57, 2001339.	3.1	26
185	Systemic Biomarkers in the Evaluation and Management of COPD Patients: Are We Getting Closer to Clinical Application?. Current Drug Targets, 2013, 14, 177-191.	1.0	26
186	Chest <sc>CT</sc> assessed comorbidities and all-cause mortality risk in <sc>COPD</sc> patients in the <sc>BODE</sc> cohort. Respirology, 2022, 27, 286-293.	1.3	26
187	Lung Reduction Surgery in Severe COPD Decreases Central Drive and Ventilatory Response to CO ₂ . Chest, 1997, 112, 902-906.	0.4	25
188	Adverse health consequences in COPD patients with rapid decline in FEV1 - evidence from the UPLIFT trial. Respiratory Research, 2011, 12, 129.	1.4	25
189	The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCs randomised controlled trial. European Respiratory Journal, 2021, 57, 2003338.	3.1	24
190	Native American Ancestry, Lung Function, and COPD in Costa Ricans. Chest, 2014, 145, 704-710.	0.4	23
191	Precision medicine in COPD exacerbations. Lancet Respiratory Medicine, 2018, 6, 657-659.	5.2	23
192	Device use errors with soft mist inhalers: A global systematic literature review and meta-analysis. Chronic Respiratory Disease, 2020, 17, 147997311990123.	1.0	23
193	β ₂ -Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT. Annals of the American Thoracic Society, 2018, 15, 608-614.	1.5	22
194	Plasma metabolomics and clinical predictors of survival differences in COPD patients. Respiratory Research, 2019, 20, 219.	1.4	22
195	Clinical and Prognostic Impact of Low Diffusing Capacity for Carbon Monoxide Values in Patients With Global Initiative for Obstructive Lung Disease I COPD. Chest, 2021, 160, 872-878.	0.4	22
196	Airflow reversibility and long-term outcomes in patients with COPD without comorbidities. Respiratory Medicine, 2014, 108, 1180-1188.	1.3	21
197	Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease. BMC Medicine, 2018, 16, 33.	2.3	21
198	Premature discontinuation during the UPLIFT study. Respiratory Medicine, 2011, 105, 1523-1530.	1.3	20

#	ARTICLE	IF	CITATIONS
199	Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2012, 13, 66.	1.4	20
200	Epicardial Adipose Tissue in Patients with Chronic Obstructive Pulmonary Disease. <i>PLoS ONE</i> , 2013, 8, e65593.	1.1	20
201	The Course of Lung Function in Middle-aged Heavy Smokers: Incidence and Time to Early Onset of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1449-1451.	2.5	20
202	Low plasma CC16 levels in smokers are associated with a higher risk for chronic bronchitis. <i>European Respiratory Journal</i> , 2015, 46, 1501-1503.	3.1	19
203	Telomere length, COPD and emphysema as risk factors for lung cancer. <i>European Respiratory Journal</i> , 2017, 49, 1601521.	3.1	19
204	Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFTA® trial. <i>Respiratory Research</i> , 2018, 19, 196.	1.4	19
205	Pharmacological Therapy of COPD. <i>Chest</i> , 2018, 154, 1404-1415.	0.4	19
206	Spirometry: A practical lifespan predictor of global health and chronic respiratory and non-respiratory diseases. <i>European Journal of Internal Medicine</i> , 2021, 89, 3-9.	1.0	19
207	Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD. <i>Respiratory Medicine</i> , 2013, 107, 1904-1911.	1.3	18
208	Validación pronóstica según los criterios de la GesEPOC 2017. <i>Archivos De Bronconeumologia</i> , 2019, 55, 409-413.	0.4	18
209	Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT. <i>Annals of the American Thoracic Society</i> , 2022, 19, 204-213.	1.5	18
210	Future perspectives in COPD. <i>Respiratory Medicine</i> , 2005, 99, S41-S48.	1.3	17
211	Obstructive Lung Disease in Mexican Americans and Non-Hispanic Whites. <i>Chest</i> , 2014, 145, 282-289.	0.4	16
212	Dissecting COPD exacerbations: time to rethink our definition. <i>European Respiratory Journal</i> , 2017, 50, 1701432.	3.1	16
213	The most beautiful COPD chart in the world: all together to end COPD!. <i>European Respiratory Journal</i> , 2019, 54, 1902047.	3.1	16
214	Natural Course of the Diffusing Capacity of the Lungs for Carbon Monoxide in COPD. <i>Chest</i> , 2021, 160, 481-490.	0.4	16
215	The EXACT-Pro: Measuring Exacerbations of COPD. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 287-288.	2.5	15
216	Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial. <i>ERJ Open Research</i> , 2021, 7, 00902-2020.	1.1	15

#	ARTICLE	IF	CITATIONS
217	Identification of Barriers to Influenza Vaccination in Patients with Chronic Obstructive Pulmonary Disease: Analysis of the 2012 Behavioral Risk Factors Surveillance Survey. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2016, 3, 620-627.	0.5	15
218	Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis. <i>BMC Pulmonary Medicine</i> , 2015, 15, 145.	0.8	14
219	Chronic Obstructive Pulmonary Disease in Hispanics. A 9-Year Update. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 15-21.	2.5	14
220	Pulmonary arterial enlargement predicts long-term survival in COPD patients. <i>PLoS ONE</i> , 2018, 13, e0195640.	1.1	13
221	Characterizing Functional Lung Heterogeneity in COPD Using Reference Equations for CT Scan-Measured Lobar Volumes. <i>Chest</i> , 2013, 143, 1607-1617.	0.4	12
222	Continuous fat-free mass decline in COPD: fact or fiction?. <i>European Respiratory Journal</i> , 2015, 46, 1496-1498.	3.1	12
223	Prognostic assessment of patients with COPD. <i>Lancet, The</i> , 2009, 374, 1885.	6.3	11
224	Assessment of five different guideline indication criteria for spirometry, including modified GOLD criteria, in order to detect COPD: data from 5,315 subjects in the PLATINO study. <i>Npj Primary Care Respiratory Medicine</i> , 2014, 24, 14075.	1.1	11
225	Clinical and prognostic heterogeneity of C and D GOLD groups. <i>European Respiratory Journal</i> , 2015, 46, 250-254.	3.1	11
226	Agreement between a simple dyspnea-guided treatment algorithm for stable COPD and the GOLD guidelines: a pilot study. <i>International Journal of COPD</i> , 2016, 11, 1217.	0.9	11
227	Simplificando las guías: los 10 mandamientos de la EPOC. <i>Archivos De Bronconeumologia</i> , 2016, 52, 179-180.	0.4	11
228	Prospective comparison of non-invasive risk markers of major cardiovascular events in COPD patients. <i>Respiratory Research</i> , 2017, 18, 175.	1.4	11
229	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. <i>Annals of the American Thoracic Society</i> , 2019, 16, 29-39.	1.5	11
230	ADAM15 expression is increased in lung CD8+ T cells, macrophages, and bronchial epithelial cells in patients with COPD and is inversely related to airflow obstruction. <i>Respiratory Research</i> , 2020, 21, 188.	1.4	11
231	International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 25-33.	2.5	11
232	Six-Minute Walking Distance in Women with COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2011, 8, 300-305.	0.7	10
233	Is COPD a Progressive Disease? A Long Term Bode Cohort Observation. <i>PLoS ONE</i> , 2016, 11, e0151856.	1.1	10
234	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging: a pooled analysis of individual patient data. <i>ERJ Open Research</i> , 2020, 6, 00253-2020.	1.1	10

#	ARTICLE	IF	CITATIONS
235	Optimal NIV Medicare Access Promotion: Patients With COPD. <i>Chest</i> , 2021, 160, e389-e397.	0.4	10
236	Pulmonary rehabilitation for COPD. <i>Postgraduate Medicine</i> , 1998, 103, 159-176.	0.9	9
237	The club cell and its protein, CC16: time to shine. <i>Lancet Respiratory Medicine</i> , 2013, 1, 757-759.	5.2	9
238	Exploring the Impact of Lung Cancer Screening on Lung Cancer Mortality of Smokers With Obstructive Lung Disease: Analysis of the NLST-ACRIN Cohort. <i>Archivos De Bronconeumologia</i> , 2021, 57, 36-41.	0.4	9
239	Executive Summary. <i>Chest</i> , 2021, 160, 1808-1821.	0.4	9
240	Predicting Mortality in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 1298-1299.	2.5	8
241	Maximal Oxygen Uptake as a Risk Predictor of NSCLC Resection in Patients With Comorbid Emphysema: Lessons From NETT. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2015, 27, 225-231.	0.4	8
242	Differences in Health-Related Quality of Life Between New Mexican Hispanic and Non-Hispanic White Smokers. <i>Chest</i> , 2016, 150, 869-876.	0.4	8
243	Somatotypes trajectories during adulthood and their association with COPD phenotypes. <i>ERJ Open Research</i> , 2020, 6, 00122-2020.	1.1	8
244	Inhaler device feature preferences among patients with obstructive lung diseases. <i>Medicine (United States)</i> , 2020, 99, 1-10.	0.4	8
245	Urgent need of a management plan for survivors of COVID-19. <i>European Respiratory Journal</i> , 2020, 55, 2000764.	3.1	8
246	External Validation and Recalculation of the CODEX Index in COPD Patients. A 3COPD Cohort Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2019, 16, 8-17.	0.7	7
247	Health effects of the Federal Bureau of Prisons tobacco ban. <i>BMC Pulmonary Medicine</i> , 2012, 12, 64.	0.8	6
248	Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT [®] trial. <i>Respiratory Research</i> , 2016, 17, 48.	1.4	6
249	Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting β_2 -agonists. <i>Journal of Medical Economics</i> , 2016, 19, 11-20.	1.0	6
250	¿Es realmente la enfermedad pulmonar obstructiva crónica una enfermedad progresiva?. <i>Archivos De Bronconeumologia</i> , 2017, 53, 362-363.	0.4	6
251	Tabaquismo en pacientes con EPOC, ¿un nuevo fenotipo clónico?. <i>Archivos De Bronconeumologia</i> , 2018, 54, 249-250.	0.4	6
252	Shorter telomeres in non-smoking patients with airflow limitation. <i>Respiratory Medicine</i> , 2018, 138, 123-128.	1.3	6

#	ARTICLE	IF	CITATIONS
253	Using the Peripheral Blood Eosinophil Count to Manage Patients with Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2019, 16, 301-303.	1.5	6
254	Smoking Pattern in Men and Women: A Possible Contributor to Sex Differences in Smoke-related Lung Diseases. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1048-1051.	2.5	6
255	Psoas Muscle Density Evaluated by Chest CT and Long-Term Mortality in COPD Patients. <i>Archivos De Bronconeumologia</i> , 2021, 57, 533-539.	0.4	6
256	Prevalence of paradoxical bronchoconstriction after inhaled albuterol. <i>Respiratory Medicine</i> , 2018, 141, 100-102.	1.3	5
257	The effect of emphysema on readmission and survival among smokers with heart failure. <i>PLoS ONE</i> , 2018, 13, e0201376.	1.1	5
258	Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment. <i>International Journal of COPD</i> , 2019, Volume 14, 1019-1031.	0.9	5
259	Methods for a Seamless Transition From Tracheostomy to Spontaneous Breathing in Patients With COVID-19. <i>Respiratory Care</i> , 2020, 65, 1773-1783.	0.8	5
260	Effects of Tiotropium on Exacerbations in Patients with COPD with Low or High Risk of Exacerbations: A Post-Hoc Analysis from the 4-Year UPLIFT [®] Trial. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> 2020, 16(6):1048-1051.	0.6	5
261	COPD heterogeneity: gender differences in the multidimensional BODE index. <i>International Journal of COPD</i> , 2007, 2, 151-5.	0.9	5
262	New treatment strategies for COPD. <i>Postgraduate Medicine</i> , 2005, 117, 27-34.	0.9	4
263	COPD (confusion over proper diagnosis) in the zone of maximum uncertainty. <i>European Respiratory Journal</i> , 2015, 46, 1525-1526.	3.1	4
264	Recommendations for the early diagnosis of COPD: the AIMAR view. <i>Multidisciplinary Respiratory Medicine</i> , 2015, 10, 6.	0.6	4
265	The EASI model: A first integrative computational approximation to the natural history of COPD. <i>PLoS ONE</i> , 2017, 12, e0185502.	1.1	4
266	Long-Acting β_2 -Agonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1641-1644.	2.5	4
267	Prognostic Validation Using GesEPOC 2017 Severity Criteria. <i>Archivos De Bronconeumologia</i> , 2019, 55, 409-413.	0.4	4
268	Impact of pre-enrolment medication use on clinical outcomes in SUMMIT. <i>ERJ Open Research</i> , 2019, 5, 00203-2018.	1.1	4
269	The Prevalence of Obstructive Lung Disease in a Lung Cancer Screening Cohort: Analysis of the National Lung Screening Trial. <i>American College of Radiology Image Network Cohort. Annals of the American Thoracic Society</i> , 2019, 16, 641-644.	1.5	4
270	Pharmacotherapy Impacts on COPD Mortality. <i>Archivos De Bronconeumologia</i> , 2021, 57, 5-6.	0.4	4

#	ARTICLE	IF	CITATIONS
271	Triple Therapy Is Also Effective in Real-World When Used in Chronic Obstructive Pulmonary Disease Patients Who Are Frequent Exacerbators. <i>Respiration</i> , 2021, 100, 93-95.	1.2	4
272	Comparison of arterial and venous blood biomarker levels in chronic obstructive pulmonary disease. <i>F1000Research</i> , 2013, 2, 114.	0.8	4
273	Women with chronic obstructive pulmonary disease: an emerging phenotype of the disease. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 821-830.	0.2	3
274	Counterpoint: Should Storefront Clinics Provide Case Finding and Chronic Care for COPD? No. <i>Chest</i> , 2014, 145, 1193-1194.	0.4	3
275	Is the Blood Eosinophil Count a Useful Biomarker in COPD? The devil is in the Details!. <i>Archivos De Bronconeumologia</i> , 2017, 53, 415-416.	0.4	3
276	Exploring the Impact of Lung Cancer Screening on Lung Cancer Mortality of Smokers With Obstructive Lung Disease: Analysis of the NLST-ACRIN Cohort. <i>Archivos De Bronconeumologia</i> , 2021, 57, 36-41.	0.4	3
277	Effect of Tiotropium on Outcomes in Patients With COPD, Categorized Using the New GOLD Grading System: Results of the UPLIFTÁ® Randomized Controlled Trial. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2015, 2, 236-251.	0.5	3
278	Does Pharmacotherapy Reduce the Rate of Decline of Lung Function in COPD?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 171-172.	2.5	2
279	The BODECOST Index (BCI): a composite index for assessing the impact of COPD in real life. <i>Multidisciplinary Respiratory Medicine</i> , 2016, 11, 10.	0.6	2
280	Documento de expertos del uso de broncodilatadores inhalados en monoterapia en el tratamiento de la EPOC estable leve-moderada. <i>Archivos De Bronconeumologia</i> , 2017, 53, 574-582.	0.4	2
281	Improving Our Aim: Targeting Therapy with Roflumilast in Patients with Severe and Very Severe Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1242-1244.	2.5	2
282	Predictors of Nebulized Arformoterol Treatment: A Retrospective Analysis of Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease*. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2019, 16, 140-151.	0.7	2
283	Regional differences in rate of FEV1 decline in COPD: lessons from SUMMIT. <i>European Respiratory Journal</i> , 2019, 53, 1900278.	3.1	2
284	<p>A Delphi Consensus Document on the Use of Single-Inhaler Fixed-Dose Triple Therapies in COPD Patients</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 1801-1811.	0.9	2
285	Chronic Obstructive Pulmonary Disease in the Twenty-First Century. <i>Clinics in Chest Medicine</i> , 2020, 41, xv-xvii.	0.8	2
286	Metabolic and cardiorespiratory effects of decreasing lung hyperinflation with budesonide/formoterol in COPD: a randomized, double-crossover, placebo-controlled, multicenter trial. <i>Respiratory Research</i> , 2020, 21, 26.	1.4	2
287	Nocturnal Hypoxemia and CT Determined Pulmonary Artery Enlargement in Smokers. <i>Journal of Clinical Medicine</i> , 2021, 10, 489.	1.0	2
288	A 62-Year-Old Woman With Chronic Obstructive Pulmonary Disease. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 2721.	3.8	1

#	ARTICLE	IF	CITATIONS
289	Is the Blood Eosinophil Count a Useful Biomarker in COPD? The devil is in the Details!. Archivos De Bronconeumologia, 2017, 53, 415-416.	0.4	1
290	Rapid decline in lung function in healthy adults predicts incident excess urinary albumin excretion later in life. BMJ Open Respiratory Research, 2017, 4, e000194.	1.2	1
291	A Historical Perspective of Pulmonary Rehabilitation. , 2018, , 3-18.		1
292	Reply to Voelkel: Cigarette Smoke Is an Endothelial Cell Toxin. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 274-275.	2.5	1
293	Functional Studies of Single-Nucleotide Polymorphisms Suggest Heterogeneity in Chronic Obstructive Pulmonary Disease due to Susceptibility of Different Cell Types. Annals of the American Thoracic Society, 2018, 15, S285-S285.	1.5	1
294	Targeting dyspnoea in patients with very severe COPD: Practical precision medicine. Respirology, 2018, 23, 1086-1087.	1.3	1
295	Muscle loss in <scp>COPD</scp>: An "imploding" phenotype in need of therapies. Respirology, 2021, 26, 8-9.	1.3	1
296	Psoas Muscle Density Evaluated by Chest CT and Long-Term Mortality in COPD Patients. Archivos De Bronconeumologia, 2021, 57, 533-539.	0.4	1
297	The use of multidimensional indices. , 0, , 143-160.		1
298	Network analysis of autopsy diagnoses: Insights into the "cause of death" from unbiased disease clustering. Journal of Pathology Informatics, 2018, 9, 35.	0.8	1
299	ANTES: Un año despu�s en la EPOC. Archivos De Bronconeumologia, 2022, 58, 291-294.	0.4	1
300	Pulmonary rehabilitation. Israel Medical Association Journal, 2003, 5, 443-8.	0.1	1
301	Selecting the Right Patient: The Achilles Heel of COPD Clinical Trials. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1051-1052.	2.5	1
302	Upper Airway Diseases. , 0, , 513-527.		0
303	Lung Volume Reduction in Patients with COPD: Physiological and Clinical Implications. Current Respiratory Medicine Reviews, 2008, 4, 312-320.	0.1	0
304	Effect of Pharmacotherapy on Rate of Decline of FEV1 in the TORCH Study. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 426-427.	2.5	0
305	Preface. Medical Clinics of North America, 2012, 96, xi-xii.	1.1	0
306	Treatment of the Stable Patient with Chronic Obstructive Pulmonary Disease. , 2012, , 553-561.		0

#	ARTICLE	IF	CITATIONS
307	Rebuttal From Dr Celli. Chest, 2014, 145, 1195-1196.	0.4	0
308	We must join forces in the battle against COPD. European Respiratory Journal, 2015, 46, 1528-1528.	3.1	0
309	Reply: Controlled Clinical Trials and Real-Life Experience with Pulmonary Rehabilitation. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 797-797.	2.5	0
310	Expert Statement on the Single-Agent Use of Inhaled Bronchodilator in the Treatment of Stable Mild-Moderate Chronic Obstructive Pulmonary Disease. Archivos De Bronconeumologia, 2017, 53, 574-582.	0.4	0
311	Failure of Low-Dose Theophylline to Prevent Exacerbations in Patients With COPD. JAMA - Journal of the American Medical Association, 2018, 320, 1541.	3.8	0
312	Enriched Systemic Biomarkers in Symptomatic Unobstructed Smokers. Chest, 2019, 155, 886-887.	0.4	0
313	Report of the Barcelona Boston Lung Conference 2020. Open Respiratory Archives, 2020, 2, 141-142.	0.0	0
314	Reply to: Thomson, to Neder et al., and to Wouters. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 112.	2.5	0
315	In memoriam, Claudio F. Donner, MD (1948â€”2021): respiratory medicine's impresario. Respiratory Medicine, 2021, 188, 106616.	1.3	0
316	Comorbidities in Patients With Chronic Obstructive Pulmonary Disease. , 2022, , 663-674.		0
317	Management Guidelines for Chronic Obstructive Pulmonary Disease. , 2011, , 81-98.		0
318	Exacerbations, Health Resource Utilization, and Costs Among Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease Treated with Nebulized Arformoterol Following a Respiratory Event. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2019, 6, 297-307.	0.5	0
319	The 7 Cardinal Sins of COPD in Spain. Archivos De Bronconeumologia, 2022, 58, 498-503.	0.4	0
320	Blood Eosinophils in Chinese COPD Participants and Response to Treatment with Combination Low-Dose Theophylline and Prednisone: A Post-Hoc Analysis of the TASCs Trial. International Journal of COPD, 2022, Volume 17, 273-282.	0.9	0
321	Novel concepts in the pharmacotherapy of chronic obstructive pulmonary disease. Pneumonologia I Alergologia Polska, 2009, 77, 82-90.	0.6	0
322	Reply to Bhatt and Ramakrishnan, et al.. American Journal of Respiratory and Critical Care Medicine, 2022, , .	2.5	0
323	[Translated article] The ANTES Program in COPD: First Year. Archivos De Bronconeumologia, 2022, 58, T291-T294.	0.4	0